- Home
- DRMA vs PRFX Comparison
DRMA vs PRFX Comparison
Compare DRMA & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- PRFX
- Stock Information
- Founded
- DRMA 2014
- PRFX 2007
- Country
- DRMA United States
- PRFX Israel
- Employees
- DRMA N/A
- PRFX N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- PRFX Health Care
- Exchange
- DRMA Nasdaq
- PRFX Nasdaq
- Market Cap
- DRMA 3.3M
- PRFX 2.8M
- IPO Year
- DRMA 2021
- PRFX 2020
- Fundamental
- Price
- DRMA $5.38
- PRFX $1.38
- Analyst Decision
- DRMA Strong Buy
- PRFX Hold
- Analyst Count
- DRMA 1
- PRFX 1
- Target Price
- DRMA $10.00
- PRFX N/A
- AVG Volume (30 Days)
- DRMA 79.8K
- PRFX 162.3K
- Earning Date
- DRMA 11-12-2025
- PRFX 11-14-2025
- Dividend Yield
- DRMA N/A
- PRFX N/A
- EPS Growth
- DRMA N/A
- PRFX N/A
- EPS
- DRMA N/A
- PRFX N/A
- Revenue
- DRMA N/A
- PRFX N/A
- Revenue This Year
- DRMA N/A
- PRFX N/A
- Revenue Next Year
- DRMA N/A
- PRFX N/A
- P/E Ratio
- DRMA N/A
- PRFX N/A
- Revenue Growth
- DRMA N/A
- PRFX N/A
- 52 Week Low
- DRMA $4.55
- PRFX $1.25
- 52 Week High
- DRMA $23.70
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- DRMA 50.49
- PRFX 47.22
- Support Level
- DRMA $4.55
- PRFX $1.34
- Resistance Level
- DRMA $5.22
- PRFX $1.50
- Average True Range (ATR)
- DRMA 0.44
- PRFX 0.08
- MACD
- DRMA 0.02
- PRFX -0.00
- Stochastic Oscillator
- DRMA 58.04
- PRFX 22.73
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.